Author

Elizabeth Janko

Morgan Adams Foundation

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Research Focus:drug response / drug discovery· 2 Approach:experimental assay· 2 Organism:human· 2 Assay:proteomics· 1

Frequent Co-Authors

Etienne P. DanisiD· 2 shared Faye M. WalkeriD· 2 shared Lays Martin SobraliD· 2 shared Nathan A. DahliD· 2 shared Pradeep Bompada· 2 shared Adam L. GreeniD· 1 shared Angela M. PierceiD· 1 shared Bethany L. Veo· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 41 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Etienne P. DanisORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Preclinical evaluation of ixazomib for high-risk pediatric brain tumors

Elizabeth Janko, Faye M. Walker, Mathew Slade, Etienne P. Danis, Pradeep Bompada, Lays Martin Sobral, Julia Chapman, Ishmeen Kaur, Simran Bal, Gabrielle Link, Nicholas McQuillan, Jean M. Mulcahy Levy, Adam L. Green, Nathan A. Dahl

This study evaluates ixazomib's efficacy against high-risk pediatric brain tumors, finding it cytotoxic but with limited CNS penetration.

bioRxiv · Sep 18, 2026 · PreprintCancer Biology

Targeting processive transcription for Myc-driven circuitry in medulloblastoma

Lays Martin Sobral, Faye M. Walker, Krishna P.C. Madhavan, Elizabeth Janko, Sahiti Donthula, Etienne P. Danis, Pradeep Bompada, Ilango Balakrishnan, Dong Wang, Angela M. Pierce, Mary M. Haag, Billie J. Carstens, Natalie Julie Serkova, Nicholas K. Foreman, Sujatha Venkataraman, , Nathan A. Dahl

This study identifies CDK9 as a conserved dependency in Myc-driven medulloblastoma and shows that CDK9 inhibition disrupts Myc-driven transcriptional programs, leading to anti-tumor effects.

Neuro-Oncology · May 12, 2025Peer-reviewedCancer Biology